9/20/2023 0 Comments Outset medicalDrexler started her career at LifeScan where she managed a variety of functions and ultimately executed the sale of the company to Johnson & Johnson. Prior to that, she founded and served as CEO at Amira Medical until its sale to Roche Diabetes Care. Most recently, she was the CEO of Sandstone Diagnostics, a life science tools company focused on increased access to high-quality diagnostic testing. “She brings a new perspective and invaluable knowledge that will help fuel our rapid growth trajectory.”ĭrexler brings extensive technical and operational leadership to her role on the Outset board. “Karen’s experience in the medtech field, using data analytics and a consumer-centric approach to creating a better patient experience, aligns beautifully with the commercial strategies we are implementing both in the home and the acute markets with Tablo,” said Outset Medical CEO Leslie Trigg. magazine’s most influential corporate directors in 2018, Drexler brings to Outset a deep understanding of how to utilize data analytics and machine learning to power the user experience, while supporting the patient at home and in the hospital setting. Drexler currently serves on the boards of ResMed (NYSE: RMD), a $31B data-driven sleep and respiratory market leader VIDA Diagnostics, developer of AI-powered lung intelligence and imaging solutions and Tivic Health, a bioelectronic medicine company. Outset Medical, Inc.(Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, is bolstering its board of directors with the appointment of Karen Drexler. Healthcare Industry Veteran Brings Digital Health Expertise and Consumer-Centric Approach to Furthering Company’s Mission of Transforming Dialysis Treatment
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |